We are live on ! Find out more
Merck & Co

Merck & Co Portfolio holdings

AUM $526M Turnover 7.14%
1-Year Est. Return 175.27%
This Fund
S&P 500
This Quarter Est. Return
+62.42%
1 Year Est. Return
+175.27%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$526M
AUM Growth
+$177M
Cap. Flow
-$47.9K
Cap. Flow %
-0.01%
Top 10 Hldgs %
99.79%
Holding
14
New
–
Increased
–
Reduced
–
Closed
1
Avg Time Held
1.3 years
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
1.3 years

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CARM icon
Carisma Therapeutics
CARM
+$47.9K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PSNL icon
1
Personalis
PSNL
$1.68B
$188M 35.75%
14,044,943
– –
2024 Q4
6 quarters
MRNA icon
2
Moderna
MRNA
$103B
$162M 30.71%
2,308,190
– –
2024 Q4
6 quarters
KYMR icon
3
Kymera Therapeutics
KYMR
$10.8B
$88.5M 16.82%
772,165
– –
2024 Q4
6 quarters
AKTS icon
4
Aktis Oncology
AKTS
$831M
$30.7M 5.83%
952,844
– –
2026 Q1
1 quarter
EIKN icon
5
Eikon Therapeutics
EIKN
$301M
$21.7M 4.13%
1,666,666
– –
2026 Q1
1 quarter
TRDA icon
6
Entrada Therapeutics
TRDA
$184M
$12.8M 2.43%
1,739,768
– –
2024 Q4
6 quarters
STRO icon
7
Sutro Biopharma
STRO
$158M
$9.04M 1.72%
272,351
– –
2024 Q4
6 quarters
ALEC icon
8
Alector
ALEC
$255M
$7.13M 1.35%
3,545,719
– –
2024 Q4
6 quarters
EVAX icon
9
Evaxion A/S
EVAX
$26.7M
$3.76M 0.72%
1,214,126
– –
2024 Q4
6 quarters
VRDN icon
10
Viridian Therapeutics
VRDN
$3.29B
$1.72M 0.33%
93,414
– –
2024 Q4
6 quarters
XLO icon
11
Xilio Therapeutics
XLO
$57.1M
$1.02M 0.19%
105,982
– –
2024 Q4
6 quarters
HURA icon
12
TuHURA Biosciences
HURA
$105M
$45.5K 0.01%
19,445
– –
2025 Q2
4 quarters
NEUP icon
13
Neuphoria Therapeutics
NEUP
$16.2M
$43.8K 0.01%
10,027
– –
2024 Q4
6 quarters
CARM icon
14
DELISTED
Carisma Therapeutics
CARM
– –
-1,473,240
Closed -$47.9K –

Similar funds

H2CM
H/2 Credit Manager Stamford, Connecticut $526M AUM 70.67% 1-Year Est. Return
Altrius Capital Management
Altrius Capital Management New Bern, North Carolina $526M AUM 20.91% 1-Year Est. Return
Unio Capital
Unio Capital Princeton, New Jersey $526M AUM 25.9% 1-Year Est. Return
West Michigan Advisors
West Michigan Advisors Holland, Michigan $526M AUM 45.54% 1-Year Est. Return
Auxano Advisors
Auxano Advisors Bellevue, Washington $528M AUM 23.67% 1-Year Est. Return
Webs Creek Capital Management
Webs Creek Capital Management Dallas, Texas $528M AUM 69.69% 1-Year Est. Return
Decagon Asset Management
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Merck & Co's Q2 2026 Portfolio in Review

As of Q2 2026, Merck & Co held 14 positions worth $526M, up 51% from $349M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Merck & Co's Q2 2026 filing shows 1 closed position. The largest sale was Carisma Therapeutics, an estimated $47.9K.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Merck & Co fully exited Carisma Therapeutics in Q2 2026, selling an estimated $47.9K.
  • Merck & Co's ten largest holdings make up 100% of its $526M portfolio in Q2 2026.
  • Merck & Co opened 0 new positions and closed 1 in Q2 2026.
  • Merck & Co's portfolio value rose 51% quarter-over-quarter to $526M.

Based on Merck & Co's 13F filing for Q2 2026, filed 7 Aug 2026.